by Halia Therapeutics | Nov 29, 2023 | News & Media, Press Releases
LEHI, Utah, Nov. 29, 2023 /PRNewswire/ — Halia Therapeutics, a clinical-stage biopharmaceutical company pioneering a novel class of small molecule medications designed to combat inflammation, today announced positive results following the... by Halia Therapeutics | Nov 27, 2023 | Press Releases
Halia will present 3 posters with new positive data and a company showcase providing an overview of its clinical programs targeting the inflammasome LEHI, Utah, Nov. 27, 2023 /PRNewswire/ — Halia Therapeutics, a clinical-stage biopharmaceutical company... 
by Halia Therapeutics | Nov 20, 2023 | Press Releases
LEHI, Utah, Nov. 20, 2023 /PRNewswire/ — Halia Therapeutics, a clinical-stage biopharmaceutical company advancing innovative medicines to treat a broad range of diseases driven by chronic inflammation and neurodegeneration, today announced... 
by Halia Therapeutics | Nov 16, 2023 | Press Releases
SALT LAKE CITY, Nov. 16, 2023 /PRNewswire/ — Halia Therapeutics, a clinical-stage biopharmaceutical company advancing innovative medicines to treat a broad range of diseases driven by chronic inflammation and neurodegeneration, today announced the... 
by Halia Therapeutics | Oct 31, 2023 | Press Releases
Company announces the appointment of Dr. David Bearss, CEO of Halia Therapeutics, as a member of the Board of Directors at BioUtah LEHI, Utah, Oct. 31, 2023 /PRNewswire/ — Halia Therapeutics, a clinical-stage biopharmaceutical company advancing innovative... by Halia Therapeutics | Oct 18, 2023 | Press Releases
LEHI, Utah, Oct. 18, 2023 /PRNewswire/ — Halia Therapeutics, a clinical-stage biopharmaceutical company advancing innovative medicines to treat a broad range of diseases driven by chronic inflammation and neurodegeneration, today announced that Jared Bearss,... by Halia Therapeutics | Aug 31, 2023 | Press Releases
SALT LAKE CITY, Aug. 31, 2023 /PRNewswire/ — Halia Therapeutics, a clinical-stage biopharmaceutical company advancing innovative medicines to treat a broad range of diseases driven by chronic inflammation and neurodegeneration, today announced they... 
by Halia Therapeutics | Aug 22, 2023 | Press Releases
The company plans to start two Phase II trials later this year, with a further Phase I trial planned for early 2024. Halia Therapeutics is planning to start two Phase II trials evaluating its lead drug HT-6184 before the end of the year, said CEO David Bearss in an... by Halia Therapeutics | Aug 16, 2023 | Press Releases
SALT LAKE CITY, Aug. 16, 2023 /PRNewswire/ — Halia Therapeutics, a clinical-stage biopharmaceutical company advancing innovative medicines to treat a broad range of diseases driven by chronic inflammation and neurodegeneration, today announced the opening of its... by Halia Therapeutics | Aug 7, 2023 | Press Releases
– Halia expects to release data from the Phase I trial in Q4 2023 SALT LAKE CITY, Aug. 7, 2023 /PRNewswire/ — Halia Therapeutics, a clinical-stage biopharmaceutical company advancing innovative medicines to treat a broad range of diseases that are driven... by Halia Therapeutics | Feb 9, 2023 | Press Releases
Halia is excited to announce that Anya Neidig, MSN, RN, has joined our clinical team as Director of Clinical Operations. Anya brings over 20 years of experience in patient care and will help advance our #NEK7 and #LRRK2 programs through multiple clinical trials in... by Halia Therapeutics | Aug 16, 2022 | Press Releases
SALT LAKE CITY (August 16, 2022) – Halia Therapeutics, the first biotechnology company to target NEK7 to block the assembly of the NLRP3 inflammasome complex, participated today in a fireside chat exploring approaches to innovate Alzheimer’s therapies at... by Halia Therapeutics | Aug 1, 2022 | Press Releases
SALT LAKE CITY (August 1, 2022) – Halia Therapeutics, a biotechnology company that has used a structure-based drug design strategy to discover a series of small molecule therapeutics targeting important mediators of inflammation, announced today that it will present a...